Huntsman Cancer Institute/Univ of Utah Network Lead Academic Participating Site

描述(由申请人提供)：亨斯迈癌症研究所(HCI)致力于将自己打造为国家癌症研究所(NCI)网络领先学术参与网站(NLAPS)，为国家临床试验网络(NCTN)计划提供领导力和强劲的收益。HCI NLAPS是西部山区唯一的学术医学中心，也是NCI指定的唯一癌症中心，吸引了来自犹他州以及爱达荷州、内华达州和怀俄明州的临床试验患者，这些地区没有学术医学中心。HCI NLAPS将与SWOG、NRG和肿瘤学临床试验联盟(联盟)NCTN小组合作，在临床试验的开发和实施方面提供科学领导，并为整个NCTN的临床试验提供可观的收益。HCI NLAPS领导团队在合作小组研究方面资历深厚，经验丰富。大卫·加夫尼博士是一位放射肿瘤学家，在RTOG和GOG的领导和参与方面有很长的历史。在犹他州大学的大力支持下，HCI有一个蓬勃发展的临床试验计划，大量的慈善支持，最先进的设施，一家专门的肿瘤医院，以及用于临床研究的集中式单点服务基础设施 进取号。我们的中心还拥有对临床研究工作有价值的独特资产，包括农村和美洲原住民人口，NCI卓越定量成像中心，以及犹他州人口数据库，后者是基于人口的家谱数据和全州医疗记录的强大研究链接。HCI对参与合作组临床试验有着坚定的承诺：每年有35%的HCI治疗收益用于NCTN试验，并始终如一地开放&GT；50项NCTN治疗试验。HCI参与NCTN研究的人数有所增加：2007年，95名患者参加了治疗性NCTN试验；2012年，HCI将达到150名治疗性NCTN登记。2011年，胡志明市是SWOG应计项目的第二个主要地点，也是三个合作小组合并组建NRG的第六个主要地点。通过作为一个以专业知识、领导能力和积极收益为特征的癌症中心，HCI将成为NCTN计划的强大合作伙伴。

DESCRIPTION (provided by applicant): Huntsman Cancer Institute (HCI) seeks to establish itself as a National Cancer Institute (NCI) Network Lead Academic Participating Site (NLAPS) to provide leadership and robust accruals for the National Clinical Trials Network (NCTN) Program. HCI is the only academic medical center and the only NCI-Designated Cancer Center in the Intermountain West, drawing clinical trials patients from across Utah as well as from Idaho, Nevada, and Wyoming, where no academic medical centers exist The HCI NLAPS will provide scientific leadership in development and conduct of clinical trials in association with SWOG, NRG, and Alliance for Clinical Trials in Oncology (ALLIANCE) NCTN Groups, as well as substantial accrual to clinical trials across the entire NCTN. The HCI NLAPS leadership team is well-qualified and experienced in cooperative group research. The PI, David Gaffney, MD, PhD, is a radiation oncologist with a long history of leadership and participation in RTOG and GOG. HCI has a vigorous and growing clinical trials program, with strong commitment from the University of Utah, substantial philanthropic support, state-of-the-art facilities, a dedicated Cancer Hospital, and a centralized single-point-of-service infrastructure for the clinical research enterprise. Our Center also has unique assets that are valuable for clinical research efforts, including rural and Native American populations, an NCI Center for Quantitative Imaging Excellence, and the Utah Population Database, a powerful research linkage of population-based genealogical data and statewide medical records. HCI has a strong, established commitment to participation in cooperative group clinical trials: 35% of HCI therapeutic accruals are annually made to NCTN trials and, consistently, >50 NCTN therapeutic trials are open. HCI's participation in NCTN research has grown: in 2007, 95 patients were enrolled on therapeutic NCTN trials; in 2012, HCI will reach >150 therapeutic NCTN enrollments. In 2011, HCI was the second leading site for SWOG accruals overall and the sixth leading site for the three cooperative groups merging to form NRG. HCI would be a strong partner to the NCTN program through its efforts as a Cancer Center characterized by expertise, leadership, and active accrual.